Prestige BioPharma Limited (KRX:950210)
South Korea flag South Korea · Delayed Price · Currency is KRW
9,620.00
-390.00 (-3.90%)
At close: Mar 9, 2026

Prestige BioPharma Ratios and Metrics

Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2019
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 2020 - 2019
Market Capitalization
115,024176,683103,966113,582137,620396,635
Upgrade
Market Cap Growth
-36.20%69.94%-8.47%-17.47%-65.30%-
Upgrade
Enterprise Value
204,060210,19744,042-6,736-150,494-63,944
Upgrade
Last Close Price
9570.0014700.008650.009450.0011450.0033000.00
Upgrade
PE Ratio
42.087.92-6.47--
Upgrade
Forward PE
-12.0112.0112.0112.01-
Upgrade
PS Ratio
6.0512.33150.88701.81--
Upgrade
PB Ratio
0.240.350.200.210.320.69
Upgrade
P/TBV Ratio
0.320.480.260.280.320.69
Upgrade
EV/Sales Ratio
10.7314.6763.92---
Upgrade
Debt / Equity Ratio
0.180.280.170.210.010.01
Upgrade
Debt / EBITDA Ratio
---9.11--
Upgrade
Net Debt / Equity Ratio
0.01-0.06-0.26-0.34-0.69-0.78
Upgrade
Net Debt / EBITDA Ratio
-0.070.662.89-14.652.5227.01
Upgrade
Net Debt / FCF Ratio
-0.050.321.951.712.9227.54
Upgrade
Asset Turnover
0.030.020.000--
Upgrade
Inventory Turnover
0.981.180.890.01--
Upgrade
Quick Ratio
0.741.051.532.247.2632.70
Upgrade
Current Ratio
1.031.271.722.317.4632.74
Upgrade
Return on Equity (ROE)
-0.86%0.81%-10.38%-0.59%-42.08%-2.07%
Upgrade
Return on Assets (ROA)
-6.42%-5.71%-5.35%0.10%-13.89%-3.01%
Upgrade
Return on Capital Employed (ROCE)
-13.30%-11.50%-11.00%0.20%-26.80%-3.10%
Upgrade
Earnings Yield
11.89%12.62%-31.66%15.47%-153.65%-1.86%
Upgrade
FCF Yield
-57.97%-52.57%-65.49%-95.65%-74.36%-4.13%
Upgrade
Buyback Yield / Dilution
-0.25%-0.44%0.22%--16.46%-20.98%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.